Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Files An 8-K Other Events

Item 8.01.Other Events

On April 10, 2017, Interpace Diagnostics Group, Inc., a Delaware
corporation (the Company), received written notice (the Letter)
from the Listing Qualifications department (the Staff) of The
NASDAQ Capital Market (Nasdaq) notifying the Company that based
on its Form 10-K for the fiscal year ended December 31, 2016,
evidencing stockholders equity of $6,531,000, the Staff has
determined that the Company complies with Nasdaq Listing Rule
5550(b)(1) and that the matter, previously disclosed by the
Company in its Current Report on Form 8-K filed November 29,
2016, has now been closed.

The foregoing description is qualified in its entirety by
reference to the full text of the Letter, which is filed as an
exhibit to this Current Report on Form 8-K and incorporated
herein by reference in its entirety.

On April 13, 2017 the Company issued a press release announcing
the receipt of the Letter, which is furnished as an exhibit to
this Current Report on Form 10-K and shall not be deemed filed
for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed to be
incorporated by reference in any registration statement or other
document filed under the Securities Act of 1933, as amended, or
the Exchange Act, except as otherwise stated in such filing.

Item 9.01.Financial Statements and Exhibits

(d)Exhibits

* Filed herewith

About Interpace Diagnostics Group, Inc. (NASDAQ:IDXG)

Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Recent Trading Information

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) closed its last trading session 00.00 at 2.19 with 228,114 shares trading hands.